Clinical trial
A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease
NCT06240455 is registered in ClinicalTrials.gov with Worg Biotherapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease
- Lead sponsor
- Worg Biotherapeutics Inc.
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- March 31, 2026
- Completion date
- September 30, 2030
- Enrollment
- 176 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.